Cita APA (7a ed.)
Ball, G., Lemieux, C., Cameron, D., & Seftel, M. D. (2022). Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada. Current Oncology, 29(3), 2021-2046.
Cita Chicago Style (17a ed.)
Ball, Graeme, Christopher Lemieux, David Cameron, y Matthew D. Seftel. "Cost-Effectiveness of Brexucabtagene Autoleucel Versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma Following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada." Current Oncology 29, no. 3 (2022): 2021-2046.
Cita MLA (9a ed.)
Ball, Graeme, et al. "Cost-Effectiveness of Brexucabtagene Autoleucel Versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma Following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada." Current Oncology, vol. 29, no. 3, 2022, pp. 2021-2046.
Precaución: Estas citas no son 100% exactas.